Cellectar Biosciences Stock Today
| CLRB Stock | USD 1.58 0.02 1.28% |
Performance0 of 100
| Odds Of DistressLess than 5
|
Cellectar Biosciences is trading at 1.58 as of the 22nd of November 2024, a 1.28 percent increase since the beginning of the trading day. The stock's open price was 1.56. Cellectar Biosciences has under 5 % chance of experiencing financial distress over the next 2 years, but has generated negative returns over the last 90 days. Equity ratings for Cellectar Biosciences are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 3rd of December 2022 and ending today, the 22nd of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 10th of November 2005 | Category Healthcare | Classification Health Care |
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. The company was founded in 2002 and is headquartered in Florham Park, New Jersey. Cellectar Biosc operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 41.27 M outstanding shares of which 1.84 M shares are currently shorted by private and institutional investors with about 8.34 trading days to cover. More on Cellectar Biosciences
Moving together with Cellectar Stock
Moving against Cellectar Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Cellectar Stock Highlights
| CEO and President and Director | James Caruso | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsCellectar Biosciences can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Cellectar Biosciences' financial leverage. It provides some insight into what part of Cellectar Biosciences' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Cellectar Biosciences (CLRB) is traded on NASDAQ Exchange in USA. It is located in 100 Campus Drive, Florham Park, NJ, United States, 07932 and employs 20 people. Cellectar Biosciences is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 65.21 M. Cellectar Biosciences conducts business under Biotechnology sector and is part of Health Care industry. The entity has 41.27 M outstanding shares of which 1.84 M shares are currently shorted by private and institutional investors with about 8.34 trading days to cover.
Cellectar Biosciences currently holds about 24.81 M in cash with (32.38 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.06, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Cellectar Biosciences Probability Of Bankruptcy
Ownership AllocationCellectar Biosciences holds a total of 41.27 Million outstanding shares. 30% of Cellectar Biosciences outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Cellectar Ownership Details
Cellectar Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Xtx Topco Ltd | 2024-06-30 | 63.3 K | |
| Bank Of America Corp | 2024-06-30 | 63.1 K | |
| Northern Trust Corp | 2024-09-30 | 61.1 K | |
| Jpmorgan Chase & Co | 2024-06-30 | 51.1 K | |
| Citadel Advisors Llc | 2024-06-30 | 50.2 K | |
| Susquehanna International Group, Llp | 2024-06-30 | 45.8 K | |
| Millennium Management Llc | 2024-06-30 | 42.6 K | |
| Jane Street Group Llc | 2024-06-30 | 41.9 K | |
| Goldman Sachs Group Inc | 2024-06-30 | 35 K | |
| Rosalind Advisors, Inc. | 2024-09-30 | 3.7 M | |
| Nantahala Capital Management, Llc | 2024-06-30 | 3.7 M |
Cellectar Biosciences Historical Income Statement
Cellectar Stock Against Markets
Cellectar Biosciences Corporate Management
| CPA CPA | CFO Sec | Profile | |
| Andrei MD | Senior Medical | Profile | |
| Shane Lea | Chief Officer | Profile | |
| Darrell Lea | Chief Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cellectar Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Cellectar Stock refer to our How to Trade Cellectar Stock guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cellectar Biosciences. If investors know Cellectar will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cellectar Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.41) | Return On Assets (1.66) | Return On Equity (7.97) |
The market value of Cellectar Biosciences is measured differently than its book value, which is the value of Cellectar that is recorded on the company's balance sheet. Investors also form their own opinion of Cellectar Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Cellectar Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cellectar Biosciences' market value can be influenced by many factors that don't directly affect Cellectar Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cellectar Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cellectar Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cellectar Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.